Abstracts Archive - Page 2276 of 2425 - ACR Meeting Abstracts

Abstract Number: 2186 • 2012 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Primary Sjögren’s syndrome
Malin V. Jonsson¹, Daniel Hammenfors², Johan G. Brun² and Roland Jonsson³, ¹Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ³Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway
Background/Purpose: Minor salivary gland biopsy is part of the diagnostic process for primary Sjögren’s syndrome (pSS), but is not suitable for repeated follow-up. Ultrasound (US)…
Abstract Number: 2187 • 2012 ACR/ARHP Annual Meeting
Safety of Minor Labial Salivary Gland Biopsy
ŽIga Rotar, Alojzija Hočevar, NatašA. Gašperšič, Branka Hostnik, Anita Antolić and Matija Tomšič, Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: Histopathological analysis of minor salivary glands is a part of the latest classification criteria for SS proposed by the American-European Consensus Group (AECG), and…
Abstract Number: 2188 • 2012 ACR/ARHP Annual Meeting
How to Better Define Inclusion Criteria in a Large Controlled Trial in Primary Sjogren Syndrome ?
Valerie Devauchelle-Pensec¹, Xavier Mariette², Jacques-Eric Gottenberg³, Raphaèle Seror⁴, Anne-Laure Fauchais⁵, Olivier Vittecoq⁶, Véronique Le Guern⁷, Jacques Morel⁸, JJ Dubost⁹, Philippe Dieude¹⁰, Eric Hachulla¹¹, Pierre yves Hatron¹², C. Larroche¹³, Aleth Perdriger¹⁴, Xavier Puechal¹⁵, Damien Sene Sr.¹⁶, Stephanie Rist¹⁷ and Alain Saraux¹⁸, ¹Department of rheumatology and unit of immunology EA2216, Brest Occidentale university, Brest, France, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ³Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁵Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁷Department of Internal Medicine, Cochin Hospital, Paris, France, ⁸Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹⁰Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ¹¹Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, ¹³Hospital University Bobigny, bobigny, France, ¹⁴Rheumatology, Hôpital Sud, Rennes, France, ¹⁵Internal Medicine, Hôpital Cochin, Paris, France, ¹⁶Department of Internal Medicine; 5 P3S post-genomic plateform, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, ¹⁷Rheumatology, Orleans Hospital, Orleans, France, ¹⁸Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France
Background/Purpose: The subsets of primary Sjögren's syndrome (pSS) patients justifying biological therapy (BT) remain a matter of debate. Our goal was [1] to describe which…
Abstract Number: 2189 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjögren’s Syndrome: Results of the Beliss Study
Salvatore De Vita¹, Raphaèle Seror², Luca Quartuccio³, Frederic Desmoulins⁴, Sara Salvin⁵, Gabriel Baron⁶, Martina Fabris⁷, Philippe Ravaud⁸, Miriam Isola⁹ and Xavier Mariette¹⁰, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, LE Kremlin-Bicetre, France, ³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁵Rheumatology Clinic, DSMB, University of Udine,, Udine, Italy, ⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ⁷Institute of Clinical Pathology, Udine, Italy, ⁸Epidemiology, Université Paris-Descartes, Paris, Paris, France, ⁹Institute of Statistics, DSMB, University of Udine, Udine, Italy, ¹⁰Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: to report the effects of anti-BAFF/BLyS antibody belimumab (BEL) on the different ogan manifestations of primary Sjögren’s syndrome (pSS), by evaluating the ESSDAI score…
Abstract Number: 2190 • 2012 ACR/ARHP Annual Meeting
Antimalarials for Sjogren’s Syndrome Treatment in Adults, Meta-Analysis
Vibian A. Coy¹, Carlos E. Granados², Diana Gil¹, Alejandro Junca¹, Daniel Jaramillo¹, Antonio A. Iglesias-Gamarra³, Jose Felix Restrepo⁴ and Federico Rondon-Herrera⁴, ¹Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Fellow of Rheumatology Universidad Nacional de Colombia, Bogotá, Colombia, ²Departamento de Medicina, facultad de medicina, Professor -Universidad Nacional de Colombia, Bogotá, Colombia, ³Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor-Universidad Nacional de Colombia, Bogota, Colombia, ⁴Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor -Universidad Nacional de Colombia, Bogota, Colombia
Background/Purpose: Sjögren´s syndrome (SS) is a chronic inflammatory autoimmune disease that is presented with lymphocytic infiltration of exocrine glands. Its secondary secretory dysfunction may involved…
Abstract Number: 2191 • 2012 ACR/ARHP Annual Meeting
Secretagogue Use in Patients with Primary Sjogren’s Syndrome
Ghaith Noaiseh¹, Joshua Baker² and Frederick B. Vivino³, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine, Penn Presbyt Med Ctr, Philadelphia, PA
Background/Purpose: Secretagogues are commonly used to treat xerostomia in primary Sjogren’s syndrome (pSS). Side effects and/or lack of efficacy sometimes result in cessation of…
Abstract Number: 2192 • 2012 ACR/ARHP Annual Meeting
Phenotypic Features of Sjögren’s Syndrome Among Patients with Low-Titer SSA/B Antibodies
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The significance of a low titer of SSA and/or SSB antibodies (SSA/B-Ab) in individuals with clinical or other laboratory findings suggestive of Sjögren’s syndrome…
Abstract Number: 2193 • 2012 ACR/ARHP Annual Meeting
Validity of Low Titers of SSA/B Antibodies in Predicting A Key Feature of Sjögren’s Syndrome
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The validity of low titers of SSA and/or SSB (SSA/B) antibodies (Ab) in the diagnosis of Sjögren’s syndrome (SS) has not been defined. We…
Abstract Number: 2194 • 2012 ACR/ARHP Annual Meeting
Cathepsin S Activity in Tears As a Marker of Sjögren’s Syndrome
S.E. Whitt¹, K. Renduchintala¹, S. Janga², M. Shah², J. Zhu³, K. Silka³, S. Bricel³, D. Bach³, M. Heur⁴, S. Christianakis⁵, J. Irvine⁴, D. Arkfeld⁶, W.J. Mack³, William Stohl⁷ and S.F. Hamm-Alvarez², ¹University of Southern California Keck School of Medicine -These authors contributed equally to this work, Los Angeles, CA, ²University of Southern California School of Pharmacy, Los Angeles, CA, ³University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Doheny Eye Institute, Los Angeles, CA, ⁵Med/Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Div of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁷Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Currently used biomarkers for Sjögren’s Syndrome (SS), such as anti-SSA/Ro or anti-SSB/La, lack sensitivity and specificity. The goal of the work presented here…
Abstract Number: 2195 • 2012 ACR/ARHP Annual Meeting
Long-Term Changes in Autoantibody Profile After Pandemic Unadjuvanted Influenza A/H1N1 Vaccine in Sjögren’s Syndrome
Sandra G. Pasoto¹, Ana C. Ribeiro¹, Vilma S.T. Viana¹, Elaine P. Leon², Cleonice Bueno¹, Mauricio Levy Neto¹, Alexander R. Precioso³, Maria do Carmo S. Timenetsky⁴ and Eloisa Bonfa¹, ¹Internal Medicine, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Instituto Butantan, São Paulo, Brazil, ⁴Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Despite WHO recommendations about the A/California/7/2009/H1N1-like virus vaccination, there are no studies evaluating its possible influence on clinical manifestations and autoantibody profile in (primary)…
Abstract Number: 2196 • 2012 ACR/ARHP Annual Meeting
Decreased Expression of TSLP in Labial Salivary Glands of Patients with pSS Is Associated with Local and Systemic Disease Parameters
M.R. Hillen¹, A. Bikker², A.a. Kruize², M. Wenting-van Wijk², F.P.J.G. Lafeber³, C.E. Hack⁴ and J.A.G. van Roon⁵, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Thymic Stromal Lymphopoietin (TSLP) is a potent immunomodulatory cytokine involved in Th2-mediated immune responses and homeostatic T-cell expansion. Reduced TSLP expression by intestinal epithelial…
Abstract Number: 2197 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren’s Syndrome Patients
Divi Cornec¹, Alain Saraux², Jacques-Olivier Pers³, Sandrine Jousse-Joulin⁴, Yves Renaudineau³, Thierry Marhadour⁵ and Valerie Devauchelle-Pensec⁶, ¹Department of rheumatology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA 2216), Brest Occidentale university, Brest, France, ³Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁴Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ⁵Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁶Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France
Background/Purpose: Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) suggest considering antinuclear antibodies (ANA) titer and rheumatoid factor (RF) positivity in patients negative…
Abstract Number: 2198 • 2012 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Primary Sjogren’s Syndrome: Any Association with IgG4 Related Sclerosing Disease?
Adlene Jebakumar¹, Carlotta Nannini², Eunhee S. Yi³, Hiroshi Sekiguchi⁴, Jay H. Ryu⁵, Cynthia S. Crowson⁶ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology Unit, Prato Hospital, Prato, Italy, ³Anatomic Pathology, Mayo Clinic, Rochester, MN, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁵Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁶Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Various forms of interstitial lung disease (ILD) are associated with primary Sjögren’s syndrome. IgG4-related sclerosing disease (ISD) is a recently described systemic fibroinflammatory disease…
Abstract Number: 2199 • 2012 ACR/ARHP Annual Meeting
Elevated IgG4 Serum Levels Among Primary Sjogren’s Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease?
Clio P. Mavragani¹, George Fragoulis², Dimitra Rontogianni³, Maria Kanariou⁴ and Haralampos M. Moutsopoulos², ¹Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Department of Pathology, Evangelismos General Hospital, Athens, Greece, ⁴Department of Immunology, "Aghia Sophia" Children's Hospital, Athens, Greece
Background/Purpose: To determine IgG4 serum levels in a cohort of patients fulfilling the classification criteria for primary Sjogren’s syndrome (pSS) and to explore whether they…
Abstract Number: 2200 • 2012 ACR/ARHP Annual Meeting
IgE Autoantibodies Against SSA and SSB in Patients with Sjögren’s Syndrome and Healthy Controls
Stamatina Danielides¹, Barbara Dema², Juan Rivera² and Gabor G. Illei³, ¹Nidcr, NIH, Bethesda, MD, ²Laboratory of Molecular Immunogenetics, NIAMS, NIH, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disorder, presenting as an autoimmune exocrinopathy. Although the pathogenesis of this disease is largely unknown, evidence indicates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].